🍀 Spring Appointment, Lucky Draw Gifts! Growth Value Issue 1️⃣7️⃣ Spring Lucky Draw Carnival Begins!
Seize Spring Luck! 👉 https://www.gate.com/activities/pointprize?now_period=17
🌟 How to Participate?
1️⃣ Enter [Plaza] personal homepage, click the points icon next to your avatar to enter [Community Center]
2️⃣ Complete plaza or hot chat tasks like posting, commenting, liking, and speaking to earn growth value
🎁 Every 300 points can draw once, 10g gold bars, Gate Red Bull gift boxes, VIP experience cards and more great prizes await you!
Details 👉 https://www.gate.com/announcements/article/
中国首批司美格鲁肽仿制药已在路上,减重药将步入“白菜价”时代
随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期,一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息,目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市,还有十余款处于三期临床,一场价格大战即将席卷。一位内分泌专家对记者表示,随着更多仿制药的上市,减重药很快就会迎来“白菜价”时代。(第一财经)